Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endovela Gé
- Development stage
- Unknown
- Lead developer
- Exeltis France
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Endovela Gé (dienogest 2 mg) is an approved small molecule drug developed and marketed by Exeltis France for the treatment of endometriosis. As a generic version of the reference drug Visanne, its active ingredient is dienogest, a synthetic oral progestin. The drug exerts its therapeutic effect by binding as an agonist to the progesterone receptor, which leads to the suppression of estrogen-driven endometrial tissue growth, thereby reducing endometriotic lesions and relieving associated pelvic pain. It is administered as a 2 mg tablet once daily on a continuous basis and is reimbursable in France.
- Brand names
- Endovela Gé
- Other names
- Dienogest
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on Endovela Gé.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endovela Gé.